Echosens

13/03/2026

🥗 March is National — and it begins with World Obesity Day on March 4.
This month offers an opportunity to raise awareness about how everyday lifestyle habits can support better long‑term health.

This year, we want to shed light on the important connection between obesity and (Metabolic Dysfunction‑Associated Steatotic Liver Disease). Both conditions are closely linked and continue to rise globally, yet some risk factors can be prevented through healthy daily habits.

🌿 Nutrition Month reminds us to take care of ourselves - whether it’s incorporating more balanced meals into our day or finding simple ways to stay active.

Let’s use this month to encourage positive routines and empower people to prioritize their health with confidence. 💪✨

10/03/2026

📰 A new clinical study is now available:
In patients following the Fontan procedure, evidence highlights the strong diagnostic and prognostic value of liver stiffness measurement using VCTE.

In this study, validated cut-off thresholds and a practical algorithm incorporating time elapsed since surgery enable accurate rule-in and rule-out of FALD.

➡️ Liver stiffness measurement by FibroScan also correlated with clinically significant events, supporting its non-invasive role in risk stratification and long-term surveillance in the clinical management of this patient population.

Learn more here 👇
🔸English: https://www.echosens.com/lsm-vcte-post-fontan-patients/
🔸Español: https://www.echosens.com/es/lsm-vcte-pacientes-post-fontan/
🔸Français : https://www.echosens.com/fr/vcte-patients-apres-fontan/
🔸Italiano: https://www.echosens.com/it/lsm-vcte-pazienti-post-fontan/
🔸Deutsch: https://www.echosens.com/de/lsm-vcte-post-fontan-patienten/

06/03/2026

📺 Echosens à l’honneur sur BFM Business
Notre CEO Dominique Legros était récemment l’invité de Pari ETI sur BFM Business, une émission animée par Patrice Begay, pour échanger sur les défis et les succès des entreprises françaises.

Dans cette interview, vous découvrirez :
🔹 Le parcours d’Echosens et le développement de FibroScan®, solution de référence pour le diagnostic non-invasif des maladies du foie
🔹 Notre approche de l’innovation au service des professionnels de santé et des patients
🔹 Notre culture RH, centrée sur le développement des talents et la collaboration
🔹 La place stratégique de l’industrialisation française dans notre modèle et la commercialisation de nos produits au niveau international

🎥 Pour visionner l’interview dans son intégralité :
https://www.bfmtv.com/economie/replay-emissions/pari-eti/video-pari-eti-patrice-begay-recoit-dominique-legros-echosens-camille-vever-vever-et-bastien-valensi-cabaia-04-03_VN-202603040953.html

VIDÉO - Ce mercredi 4 mars, Dominique Legros, directeur général d'Echosens, Camille Vever, présidente-directrice générale de Vever, et Bastien Valensi, fondateur de Cabaïa, étaient les invités dans l'émission Pari ETI présentée par Patrice Bégay. Pari ETI est à voir ou écouter tous le...

04/03/2026

🌍 World Obesity Day – March 4th
People living with obesity are at greater risk of developing chronic diseases such as diabetes, cardiovascular disease, and certain cancers. March 4 is , a key opportunity to raise awareness and take collective action.

Obesity is also a major risk factor for (Metabolic dysfunction-associated steatotic liver disease), the most common chronic liver disease worldwide.
MASLD is characterized by an accumulation of fat in the liver, often driven by poor diet and a sedentary lifestyle. If not diagnosed early, it can progress to , leading to irreversible liver damage such as cirrhosis or liver cancer.

🩺 A non-invasive exam with FibroScan® can help detect these conditions early and support better patient management.

➡️ On this World Obesity Day, let’s break down stigma, improve understanding of the root causes, and support patients in reducing complications and their risk of developing additional chronic diseases.

Obesity affects us all—whether your motivation is your child, your community, your health, or your hope for a better, fairer world.

27/02/2026

📰 “In my experience, when patients see their FibroScan® results—when they realize their liver is carrying a burden they never suspected—it’s often the wake-up call that finally gets them to act, whether that’s starting a new medication, meeting with a nutritionist, or making the lifestyle changes we’ve been recommending for years.” — Martin Grajower, Endocrinologist

👉 Read more in Dr. Grajower’s paper “Unlocking Better Patient Outcomes: Why Liver Health Is the Key to Metabolic Wellness”: https://www.echosens.com/en-us/wp-grajower/

23/02/2026

👏 A powerful perspective from the front lines of primary care.

Dr. Jinsong Zhang captures a challenge many clinicians face every day: motivating patient behavior change when metabolic risk is invisible and abstract.

Dr. Zhang explores how objective, visual data can reshape conversations around metabolic health—helping patients move from vague concern to real understanding. When patients can see what’s happening in their bodies, the discussion becomes clearer, more personal, and far more actionable.

His perspective reinforces an important truth: earlier, data-driven insights don’t just support better clinical decisions—they help patients truly engage with their health.

We’re grateful for physicians like Dr. Zhang who are advancing patient-centered, data-informed care in primary care—where earlier understanding can make all the difference.

🔗 https://www.physiciansweekly.com/post/seeing-is-believing-how-objective-data-transforms-metabolic-care

Dr. Jinsong Zhang explains why helping patients visualize invisible metabolic risks can drive better adherence and outcomes.

20/02/2026

🎉 Echosens is proud highlight Good Samaritan Hospital as part of the !

The team leverages FibroScan® to enhance their metabolic health approach by providing non-invasive, point-of-care liver and spleen health assessments for patients at risk for MASLD/MASH.

By integrating FibroScan®, their team is helping patients get answers faster, monitor disease progression, and engage in meaningful conversations about prevention and treatment.

👏 Congratulations, Good Samaritan Hospital! Echosens is honored to support your mission to improve liver and metabolic health outcomes for patients in Indiana.

18/02/2026

The conference begins today and runs until February 20 in Madrid!
Come meet our team at booth #1 to discover the latest product innovations and learn about the new generation of FibroScan® devices equipped with Guided VCTE™ technology. Stop by for a scan demonstration!

13/02/2026

🎉 Celebrating the Opening Ceremony of our first Center of Excellence in APAC!

On February 6, 2026, we proudly inaugurated the Center of Excellence at Yonsei University Hospital.

This achievement was made possible thanks to the strong partnership and continuous support of Prof. Seung Up Kim, with whom we share a clear and ambitious mission:
1️⃣ Educate local General Practitioners in Korea on the essential role of identifying and screening MASLD patients through our Local Liver Education Program.
2️⃣ Support hepatologists across APAC by sharing best‑practice workflows and demonstrating the clinical value of FibroScan® in the management of liver health.

This Center of Excellence marks a significant step forward in advancing liver disease awareness, early diagnosis, and clinical collaboration throughout the region.

Excited for the journey ahead and the positive impact we will continue to create together!

11/02/2026

📰 A new clinical study is now available:
In patients with severe alpha-1 antitrypsin deficiency (AATD), this recent study shows that LSM by FibroScan® is proving to be an outstanding prognostic tool for predicting major adverse liver outcomes.

Current recommendations support systematic screening and longitudinal monitoring with clear LSM cut-off values to guide clinical decisions—below 8 kPa, 8-13 kPa, and 13 kPa or higher.
These benchmarks help determine when patients need closer monitoring, specialist referral, or might benefit from liver-directed therapies.

➡️ Learn more here:
🔸English: https://www.echosens.com/clinical-utility-vcte-alpha-1-antitrypsin-deficiency/
🔸Español: https://www.echosens.com/es/utilidad-clinica-vcte-alfa-1-antitripsina/
🔸Français : https://www.echosens.com/fr/mesure-vcte-deficit-alpha-1-antitrypsine/
🔸Italiano: https://www.echosens.com/it/utilita-clinica-vcte-alfa-1-antitripsina/
🔸Deutsch: https://www.echosens.com/de/vcte-alpha-1-antitrypsin-mangel/

09/02/2026

How does a leading endocrinologist approach MASLD and MASH screening with FibroScan®?

📹 Hear it straight from the source—Martin Grajower, MD.

“And frankly, I don’t remember anybody ever saying no.”

For more insights from Dr. Grajower, read “Unlocking Better Patient Outcomes: Why Liver Health Is the Key to Metabolic Wellness”: https://www.echosens.com/en-us/wp-grajower/

04/02/2026

🌍 Today is World Cancer Day.
Behind every diagnosis is a person, a family, a story. But often, liver cancer remains silent until it’s too late — leading to a life-altering diagnosis at an advanced stage.

Raising awareness and improving access to non-invasive diagnostic solutions like FibroScan® are key steps toward earlier intervention and better patient outcomes.

➡️ Let’s turn awareness into action and help build a future together where cancer is detected earlier and treated better.


World Cancer Day